Header Logo

Connection

THOMAS MONATH to Viral Envelope Proteins

Back to Details
This is a "connection" page, showing publications THOMAS MONATH has written about Viral Envelope Proteins.
THOMAS MONATH
Connection Strength
3.244
Viral Envelope Proteins
  1. rVSV?G-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model. Viruses. 2025 Feb 28; 17(3).
    View in: PubMed
    Score: 0.905
  2. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. Vaccine. 2017 08 16; 35(35 Pt A):4465-4469.
    View in: PubMed
    Score: 0.531
  3. Analysis of ChimeriVax Japanese Encephalitis Virus envelope for T-cell epitopes and comparison to circulating strain sequences. Vaccine. 2007 Nov 19; 25(47):8077-84.
    View in: PubMed
    Score: 0.271
  4. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J Virol. 2004 Sep; 78(18):9998-10008.
    View in: PubMed
    Score: 0.219
  5. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J Virol. 2002 Feb; 76(4):1932-43.
    View in: PubMed
    Score: 0.183
  6. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol. 2000 Feb; 74(4):1742-51.
    View in: PubMed
    Score: 0.159
  7. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology. 1999 May 10; 257(2):363-72.
    View in: PubMed
    Score: 0.151
  8. Assessment of the ability of V920 recombinant vesicular stomatitis-Zaire ebolavirus vaccine to replicate in relevant arthropod cell cultures and vector species. Hum Vaccin Immunother. 2018 04 03; 14(4):994-1002.
    View in: PubMed
    Score: 0.138
  9. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. CMAJ. 2017 Jun 19; 189(24):E819-E827.
    View in: PubMed
    Score: 0.133
  10. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector. Clin Vaccine Immunol. 2017 Jan; 24(1).
    View in: PubMed
    Score: 0.129
  11. Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection. Vaccine. 2016 Apr 12; 34(17):1993-9.
    View in: PubMed
    Score: 0.122
  12. Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol. 2001 Jan; 75(2):934-42.
    View in: PubMed
    Score: 0.042
  13. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol. 2000 Jun; 74(12):5477-85.
    View in: PubMed
    Score: 0.041
  14. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine. 1999 Apr 09; 17(15-16):1869-82.
    View in: PubMed
    Score: 0.038
  15. Safety and immunogenicity of the rVSV?G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis. 2017 08; 17(8):854-866.
    View in: PubMed
    Score: 0.033
  16. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J Infect Dis. 1996 Aug; 174(2):256-61.
    View in: PubMed
    Score: 0.031
  17. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. N Engl J Med. 2017 01 26; 376(4):330-341.
    View in: PubMed
    Score: 0.028
  18. Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccination. J Infect Dis. 2011 Feb 15; 203(4):513-22.
    View in: PubMed
    Score: 0.021
  19. Dengue 2 virus envelope protein expressed by a recombinant vaccinia virus fails to protect monkeys against dengue. J Gen Virol. 1988 Aug; 69 ( Pt 8):1921-9.
    View in: PubMed
    Score: 0.018
  20. Yellow fever monoclonal antibodies: type-specific and cross-reactive determinants identified by immunofluorescence. Am J Trop Med Hyg. 1984 Jul; 33(4):695-8.
    View in: PubMed
    Score: 0.014
  21. Host-range restriction of chimeric yellow fever-West Nile vaccine in fish crows (Corvus ossifragus). Am J Trop Med Hyg. 2003 Jul; 69(1):78-80.
    View in: PubMed
    Score: 0.013
  22. Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein. Virology. 1983 Feb; 125(1):8-17.
    View in: PubMed
    Score: 0.012
  23. Cloning, expression and functional activities of a single chain antibody fragment directed to fusion protein of respiratory syncytial virus. Immunotechnology. 1996 Sep; 2(3):219-28.
    View in: PubMed
    Score: 0.008
  24. Attenuation of wild-type yellow fever virus by passage in HeLa cells. J Gen Virol. 1990 Oct; 71 ( Pt 10):2301-6.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.